SCHEMBL26647359

SCHEMBL26647359

COc1c(N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)ccnc1Cl

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ATR Q13535 1/20 0.43
POLB P06746 1/20 0.36
SSTR4 P31391 1/20 0.36
SYK P43405 1/20 0.33
MT-CO2 P00403 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
LMNA P02545 2/20 0.31
KMT2A Q03164 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 2/20 0.30
KDM4E B2RXH2 1/20 0.30
HSD17B10 Q99714 1/20 0.30
CNR2 P34972 1/20 0.30
PAX8 Q06710 1/20 0.30
PDPK1 O15530 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31700922 0.89 ATR (0.46) ATRPOLBSSTR4MT-CO2SMN1; SMN2
SCHEMBL21605151 0.84 ATR (0.43) ATRPOLBSSTR4SYKMT-CO2
SCHEMBL31751389 0.82 ATR (0.41) ATRPOLBSSTR4SYKMT-CO2
SCHEMBL17362914 0.76 MKNK2 (0.41) ATRMT-CO2PDPK1
SCHEMBL31352713 0.75 SSTR4 (0.41) ATRPOLBSSTR4MT-CO2SMN1; SMN2
SCHEMBL22582911 0.73 ATR (0.40) ATRPOLBSSTR4SYKMT-CO2
SCHEMBL21332052 0.72 PDPK1 (0.34) ATRSYKMT-CO2ALDH1A1CNR2
SCHEMBL21500055 0.72 ATR (0.59) ATRPOLB
SCHEMBL30204974 0.72 SSTR4 (0.44) ATRSSTR4PDPK1
SCHEMBL31701240 0.72 ATR (0.59) ATRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 US disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 EP disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 US disclosed
WO-2022240876-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 ATR 750/4885POLB 285/4885SSTR4 3171/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 ATR 750/4885POLB 285/4885SSTR4 3171/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 ATR 750/4885POLB 285/4885SSTR4 3171/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 ATR 750/4885POLB 285/4885SSTR4 3171/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 ATR 738/4885POLB 271/4885SSTR4 3233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.